The purpose of this study is to test whether a new drug regimen will reduce the chances of side effects but be just as effective as the usual treatment for HER2-positive, ER-negative and node negative breast cancer.
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Liquid-Biopsy Monitoring for Patients not yet Eligible for Screening and Enrollment
Oral presentation by Dr Laura Dawson at the ASCO Gastrointestinal Cancer Symposium 2023 of results for the CCTG HE1 phase III study of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Canadian Cancer Society announces details of research funding for low-survival cancers, the CCTG Breakthrough Grant Application lead by Dr Marshall Pitz, has received $ 1,549,130 over 5 years. Brain cancers that are classified as grade 2 or 3 gliomas are incurable and when they recur after treatment, the lack of effective therapies for these hard-to-treat cancers leads to very poor outcomes. With the 5-year survival rate after recurrence approaching 0%, there is an urgent need for new, effective therapies. Currently, there are no clinical trials in Canada testing new and promising treatments at the time of recurrence.
CCTG former Directors joint statement regarding US requirements for identity proofing and multi-factor authentication
Practice changing data presented in endometrial cancer that demonstrates improved progression-free survival outcomes with the addition of Pembrolizumab to chemotherapy for women with advanced or recurrent endometrial cancer.
CCTG HN11 SELECT has now opened to accrual across Canada and sites in the US. The trial is a randomized, controlled, phase III clinical trial for patients with lateralized oropharyngeal carcinoma (OPC)
A new Canadian trial designed and led by Sunnybrook Health Sciences Centre will determine whether Stereotactic Ablative Body Radiotherapy (SABR) can replace the standard brachytherapy boost for men with unfavourable risk prostate cancer.
Three CCTG trials were recently awarded nearly $7.5M from the Canadian Institutes of Health Research (CIHR) 2022 Spring Project Grant competition.
The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.
Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS
Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma
STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Med-Gut Tumours
Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment (ASCENDE-SBRT)
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS
STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study
Neoadjuvant Platform Trial in Surgically Resectable NSCLC
A Phase II Study of RP-6306 in Patients with Advanced Cancer
De-escalation of Chemo in HER-2+, ER-, Node-negative, breast cancer patients who achieved complete response after chemo and Dual HER-2 blOckade (DECRESCENDO)
Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.
CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
The establishment of the Britton Smith Foundation Clinical Trials Fund. A thank you from Doug Kane, senior manager, Canadian Cancer Society FLA & The Waterways Community Office.
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
J Clin Oncol 41: TPS259 - TPS259, 2023Morris VK;Yothers G;Kopetz S;Jacobs SA;Lucas PC;Iqbal A;Boland PM;Deming DA;Scott AJ;Lim HJ;Hong TS;Wolmark N;George TJ;
J Clin Oncol 41: TPS260 - TPS260, 2023Lieu CH;Lin Y;Kopetz S;Jacobs SA;Lucas PC;Sahin IH;Deming DA;Philip PA;Hong TS;Rojas-Khalil Y;Loree JM;Wolmark N;Yothers G;George TJ;Dasari A;
J Clin Oncol 41: 124 - 124, 2023Solar Vasconcelos JP;Chen N;Tu D;Brule SY;Goodwin RA;Jonker DJ;Price TJ;Zalcberg JR;Moore MJ;Karapetis CS;Siu LL;Shapiro JD;Simes J;O'Callaghan CJ;Loree JM;
J Clin Oncol 41: 180 - 180, 2023Loree JM;Madison R;O'Callaghan CJ;Brown CJ;Tu D;Jonker DJ;Sherry M;Fine AD;Huang Y;Camara W;Pokharel P;Aleshin A;Oxnard GR;Kennecke HF;
J Clin Oncol 41: 183 - 183, 2023Ma LX;Loree JM;Jonker DJ;Kennecke HF;Berry SR;Couture F;Ahmad CE;Goffin JR;Kavan P;Harb M;Colwell B;Samimi S;Samson B;Abbas T;Aucoin N;Aubin F;Koski SL;Tu D;O'Callaghan CJ;Chen EX;
J Clin Oncol 41: LBA294 - LBA294, 2023Pavlakis N;Shitara K;Sjoquist KM;Martin AJ;Jaworski A;Yip S;Bang YJ;Alcindor T;O'Callaghan CJ;Tebbutt NC;Strickland A;Rha SY;Lee KW;Zalcberg JR;Price TJ;Simes J;Goldstein D;
J Clin Oncol 41: LBA492 - LBA492, 2023Dawson LA;Fairchild AM;Dennis K;Mahmud A;Stuckless TL;Vincent F;Roberge D;Follwell M;Wong RKW;Jonker DJ;Knox JJ;Zimmermann C;Wong P;Purdie T;Ringash J;Barry AS;Gaudet M;Tu D;Wong RK;O'Callaghan CJ;
